No coercive steps against drug firms for FDCs already in market, says HC

Image
Press Trust of India New Delhi
Last Updated : Sep 18 2018 | 5:30 PM IST

The Delhi High Court said Tuesday that no coercive steps be taken against drug companies for FDCs already in market, subject to stopping of their manufacturing.

Justice Vibhu Bakhru granted the relief to some drug manufacturers after they approached the high court.

It had said earlier that no coercive steps be taken against Indian pharma major Wockhardt for sale of stock, already in the market, of its anti-inflammatory medicine which has been banned, subject to the company stopping further production of the drug.

The court, in an interim order, had said the medicine, one of 328 fixed dose combination (FDC) drugs banned by the Centre a week ago, has been in the market for past 11 years and its stocks would already be in the distribution network.

The ministry by its September 7 notification had banned the manufacture, sale and distribution of 328 FDC drugs. FDCs are two or more drugs combined in a fixed ratio into a single dosage form.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 18 2018 | 5:30 PM IST

Next Story